Remote monitoring for HR+ HER2- breast cancer on CDK4/6 inhibitors
Part of Cancer, Skin clinical trials.
This study tests a new way to monitor patients remotely while they take CDK4/6 inhibitors and hormone therapy for HR+ HER2- breast cancer. It aims to make care more convenient and catch problems early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have HR+ HER2- breast cancer that cannot be removed with surgery or cured with radiation.
- You must have been on CDK4/6 inhibitor and hormone therapy for at least 2 months for advanced breast cancer.
- Your cancer must not have gotten worse (no disease progression) according to your doctor.
- You must be able to take care of yourself (ECOG performance status 0, 1, or 2).
- You must not have other current cancer or be on other cancer treatments.
- You must not have serious mental or memory problems that would make it hard to understand the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well CDK4/6 inhibitors (a type of targeted therapy) work in real-world patients with HR+/HER2- advanced breast cancer. By collecting medical data from people treated at this hospital, doctors hope to learn more about the effectiveness and safety of these drugs in everyday practice.
This study looks at how well CDK4/6 inhibitors combined with hormone therapy work in real-world settings for people with a certain type of advanced breast cancer (HR+/HER2-). It aims to understand the best treatment path and what happens next.
This trial studies how CDK4/6 medicines fit into treatment for people with advanced hormone receptor–positive breast cancer that cannot be cured with surgery or radiation. It may help doctors understand the best way to use these medicines for disease that has returned or spread.
This trial tests whether an AI-powered management program can improve mental health and daily habits for people with HR+/HER2- breast cancer who are taking CDK4/6 inhibitor pills at home. It is designed to help you feel supported and stay on track with your rehabilitation plan.
This trial tests giving a CDK4/6 inhibitor (a drug that blocks cancer cell growth) at the same time as radiation after surgery. It is for women with a specific type of breast cancer (hormone receptor-positive, HER2-negative) that has a high risk of coming back.
This study looks at how gut bacteria affect response to a type of targeted therapy (CDK4/6 inhibitors) combined with hormone therapy in breast cancer that is hormone receptor-positive and HER2-negative. It may help find out why some people respond better to treatment and could lead to better personalized care.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.